tiprankstipranks
Top Stocks
Top Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
ETF CenterSPY ETFQQQ ETF
Stock Comparison
ChatGPT StocksValue StocksAirline StocksAI StocksOil StocksBank StocksFAANG StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
Market Movers
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
ETF Center
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Dividend Stocks
ChatGPT Stocks
Airline Stocks
AI Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
ETF News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

CLDX Stock Latest News

Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
Press ReleasesCelldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
2d ago
CLDX
Celldex reports Q4 EPS (56c), consensus (59c)
The FlyCelldex reports Q4 EPS (56c), consensus (59c)
1M ago
CLDX
Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update
Press ReleasesCelldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update
1M ago
CLDX
Celldex presents data from barzolvolimab Phase 1b study in CSU
The FlyCelldex presents data from barzolvolimab Phase 1b study in CSU
1M ago
CLDX
Cantor biotech/biopharma analysts hold an analyst/industry conference call
The FlyCantor biotech/biopharma analysts hold an analyst/industry conference call
1M ago
ALLK
CLDX
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
Press ReleasesCelldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
1M ago
CLDX
Cantor biotech/biopharma analysts hold an analyst/industry conference call
The FlyCantor biotech/biopharma analysts hold an analyst/industry conference call
1M ago
ALLK
CLDX
Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
Press ReleasesCelldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
1M ago
CLDX
Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference
Press ReleasesCelldex Therapeutics to Present at SVB Securities Global Biopharma Conference
1M ago
CLDX
Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023
Press ReleasesCelldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023
2M ago
CLDX
Celldex has key catalysts in 2023, says Cantor Fitzgerald
The FlyCelldex has key catalysts in 2023, says Cantor Fitzgerald
3M ago
CLDX
Sell these stocks now, proven algorithm says
The FlySell these stocks now, proven algorithm says
3M ago
GH
CCL
Third Harmonic Bio downgraded to Market Perform at LifeSci Capital
The FlyThird Harmonic Bio downgraded to Market Perform at LifeSci Capital
4M ago
ALLK
CLDX
Third Harmonic ‘further behind’ Celldex after discontinuation, says Guggenheim
The FlyThird Harmonic ‘further behind’ Celldex after discontinuation, says Guggenheim
4M ago
CLDX
THRD
Celldex to host conference call
The FlyCelldex to host conference call
4M ago
CLDX
Celldex presents positive Phase 1b interim data from barzolvolimab in urticaria
The FlyCelldex presents positive Phase 1b interim data from barzolvolimab in urticaria
4M ago
CLDX
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022
Press ReleasesCelldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022
4M ago
CLDX
Celldex to host conference call
The FlyCelldex to host conference call
4M ago
CLDX
Celldex to host conference call
The FlyCelldex to host conference call
4M ago
CLDX
Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022
Press ReleasesCelldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022
4M ago
CLDX
Celldex to Participate in Upcoming November Investor Conferences
Press ReleasesCelldex to Participate in Upcoming November Investor Conferences
5M ago
CLDX
Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Press ReleasesCelldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update
5M ago
CLDX
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert CenterEtf Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.